Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688906 · ClinicalTrials.gov registry record
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
A clinical trial, sponsored by Freenome Holdings.
- Completed
- Registry status
- 3,275
- Enrollment target
NCT03688906 is a clinical trial that has completed, run by Freenome Holdings. The registered enrollment target is 3,275 participants.
The verdict
NCT03688906 has completed, sponsored by Freenome Holdings.
- COMPLETED
- Registry status
- 3,275 participants
- Enrollment target
Study Summary
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,275 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2019-11-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688906
The ClinicalTrials.gov registry entry for NCT03688906 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Freenome Holdings, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03688906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688906 about?
NCT03688906 is a clinical study titled "AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test". Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from ...
What is the current status of trial NCT03688906?
This trial is currently completed. The enrollment target is 3,275 participants. The study started on 2018-01-12. Estimated completion is 2019-11-25.
Who is sponsoring clinical trial NCT03688906?
This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.